Soon Koo Baik

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/595916/publications.pdf

Version: 2024-02-01

84 papers	3,884 citations	101384 36 h-index	128067 60 g-index
90 all docs	90 docs citations	90 times ranked	4919 citing authors

#	Article	IF	Citations
1	Multidimensional Biomarker Analysis Including Mitochondrial Stress Indicators for Nonalcoholic Fatty Liver Disease. Gut and Liver, 2022, 16, 171-189.	1.4	2
2	Autoimmune Hepatitis Following Vaccination for SARS-Cov-2 in Korea: Coincidence or Autoimmunity?. Journal of Korean Medical Science, 2022, 37, e116.	1.1	18
3	Application of ultrasound for the diagnosis of cirrhosis/portal hypertension. Journal of Medical Ultrasonics (2001), 2022, 49, 321-331.	0.6	7
4	Mesenchymal stem cell therapy for liver disease: current status and future perspectives. Current Opinion in Gastroenterology, 2021, 37, 216-223.	1.0	11
5	The longitudinal outcomes of applying non-selective beta-blockers in portal hypertension: real-world multicenter study. Hepatology International, 2021, 15, 424-436.	1.9	3
6	Hepatopulmonary syndrome is related to the development of acute-on-chronic liver failure and poor prognosis in cirrhotic patients. Hepatology International, 2021, 15, 1207-1214.	1.9	8
7	Mesenchymal stem cells to treat liver diseases. Annals of Translational Medicine, 2020, 8, 563-563.	0.7	9
8	Application of Hepatic Venous Pressure Gradient to Predict Prognosis in Cirrhotic Patients with a Low Model for End-stage Liver Disease Score. Diagnostics, 2020, 10, 805.	1.3	1
9	Ca2+-activated mitochondrial biogenesis and functions improve stem cell fate in Rg3-treated human mesenchymal stem cells. Stem Cell Research and Therapy, 2020, 11, 467.	2.4	11
10	Bone Marrow-Derived Mesenchymal Stem Cells Isolated from Patients with Cirrhosis and Healthy Volunteers Show Comparable Characteristics. International Journal of Stem Cells, 2020, 13, 394-403.	0.8	6
11	Hepatocellular carcinoma in old age: are there any benefits of liver resection in old age?. Annals of Surgical Treatment and Research, 2020, 99, 65.	0.4	4
12	Mesenchymal Stem Cells for the Treatment of Liver Disease: Present and Perspectives. Gut and Liver, 2020, 14, 306-315.	1.4	47
13	Application of Baveno Criteria and Modified Baveno Criteria with Shear-wave Elastography in Compensated Advanced Chronic Liver Disease. Journal of Korean Medical Science, 2020, 35, e249.	1.1	5
14	Varices on computed tomography are surrogate of clinically significant portal hypertension and can predict survival in compensated cirrhosis patients. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 450-457.	1.4	10
15	Response-Related Factors of Bone Marrow-Derived Mesenchymal Stem Cells Transplantation in Patients with Alcoholic Cirrhosis. Journal of Clinical Medicine, 2019, 8, 862.	1.0	1
16	The New Cutoff Value of the Hepatic Venous Pressure Gradient on Predicting Long-Term Survival in Cirrhotic Patients. Journal of Korean Medical Science, 2019, 34, e223.	1.1	4
17	Perspectives on Acute Hepatitis A Control in Korea. Journal of Korean Medical Science, 2019, 34, e230.	1.1	8
18	Synergistic effects of simvastatin and bone marrow-derived mesenchymal stem cells on hepatic fibrosis. Biochemical and Biophysical Research Communications, 2018, 497, 264-271.	1.0	19

#	Article	IF	Citations
19	Mesenchymal stromal cell therapy for liver diseases. Journal of Hepatology, 2018, 68, 1272-1285.	1.8	144
20	Adipose-derived stem cells ameliorate colitis by suppression of inflammasome formation and regulation of M1-macrophage population through prostaglandin E2. Biochemical and Biophysical Research Communications, 2018, 498, 988-995.	1.0	61
21	Novelties in the pathophysiology and management of portal hypertension: new treatments on the horizon. Hepatology International, 2018, 12, 112-121.	1.9	17
22	Impact of Bacterial Translocation on Hepatopulmonary Syndrome: A Prospective Observational Study. Digestive Diseases and Sciences, 2018, 63, 248-256.	1.1	9
23	Role of the renin-angiotensin system in hepatic fibrosis and portal hypertension. Korean Journal of Internal Medicine, 2018, 33, 453-461.	0.7	63
24	Efficacy of Pegylated Interferon Monotherapy versus Sequential Therapy of Entecavir and Pegylated Interferon in Hepatitis B e Antigen-Positive Hepatitis B Patients. Chinese Medical Journal, 2018, 131, 1645-1651.	0.9	7
25	The Impact of Sarcopenia and Its Rate of Change on Prognostic Value of Liver Cirrhosis. Journal of Korean Medical Science, 2018, 33, e334.	1.1	2
26	Chronic Hepatitis B Infection Is Significantly Associated with Chronic Kidney Disease: a Population-based, Matched Case-control Study. Journal of Korean Medical Science, 2018, 33, e264.	1.1	13
27	Impact of sarcopenia on prognostic value of cirrhosis: going beyond the hepatic venous pressure gradient and MELD score. Journal of Cachexia, Sarcopenia and Muscle, 2018, 9, 860-870.	2.9	101
28	Expression of Fibroblast Growth Factor 21 and Î²-Klotho Regulates Hepatic Fibrosis through the Nuclear Factor-ÎºB and c-Jun N-Terminal Kinase Pathways. Gut and Liver, 2018, 12, 449-456.	1.4	33
29	Relative Adrenal Insufficiency in Patients with Cirrhosis: A Systematic Review and Meta-Analysis. Digestive Diseases and Sciences, 2017, 62, 1067-1079.	1.1	37
30	1-Methyl-L-tryptophan promotes the apoptosis of hepatic stellate cells arrested by interferon-Î³ by increasing the expression of IFN-Î³RÎ², IRF-1 and FAS. International Journal of Molecular Medicine, 2017, 40, 576-582.	1.8	13
31	Prognostic value of sarcopenia in patients with liver cirrhosis: A systematic review and meta-analysis. PLoS ONE, 2017, 12, e0186990.	1.1	237
32	Transient elastography versus hepatic venous pressure gradient for diagnosing portal hypertension: a systematic review and meta-analysis. Clinical and Molecular Hepatology, 2017, 23, 34-41.	4.5	51
33	Diagnostic Accuracy of Hepatic Vein Arrival Time Performed with Contrast-Enhanced Ultrasonography for Cirrhosis: A Systematic Review and Meta-Analysis. Gut and Liver, 2017, 11, 93-101.	1.4	24
34	Rifaximin and Propranolol Combination Therapy Is More Effective than Propranolol Monotherapy for the Reduction of Portal Pressure: An Open Randomized Controlled Pilot Study. Gut and Liver, 2017, 11, 702-710.	1.4	27
35	Clinical Implications of the Serum Apelin Level on Portal Hypertension and Prognosis of Liver Cirrhosis. Gut and Liver, 2016, 10, 109.	1.4	28
36	Transplantation with autologous bone marrowâ€derived mesenchymal stem cells for alcoholic cirrhosis: Phase 2 trial. Hepatology, 2016, 64, 2185-2197.	3.6	213

#	Article	IF	Citations
37	The need for histological subclassification of cirrhosis: a systematic review and metaâ€analysis. Liver International, 2016, 36, 847-855.	1.9	15
38	Reninâ€“angiotensin system inhibitors and fibrosis in chronic liver disease: a systematic review. Hepatology International, 2016, 10, 819-828.	1.9	47
39	Effect of Function-Enhanced Mesenchymal Stem Cells Infected With Decorin-Expressing Adenovirus on Hepatic Fibrosis. Stem Cells Translational Medicine, 2016, 5, 1247-1256.	1.6	35
40	Incremental Predictive Value of Serum AST-to-ALT Ratio for Incident Metabolic Syndrome: The ARIRANG Study. PLoS ONE, 2016, 11, e0161304.	1.1	27
41	Adult Stem Cell Therapy in Chronic Liver Diseases. Hanyang Medical Reviews, 2015, 35, 236.	0.4	2
42	Therapeutic Effects of Mesenchymal Stem Cells for Patients with Chronic Liver Diseases: Systematic Review and Meta-analysis. Journal of Korean Medical Science, 2015, 30, 1405.	1.1	52
43	The Accuracy of Ultrasonography for the Evaluation of Portal Hypertension in Patients with Cirrhosis: A Systematic Review. Korean Journal of Radiology, 2015, 16, 314.	1.5	24
44	Diagnostic and Prognostic Values of Noninvasive Predictors of Portal Hypertension in Patients with Alcoholic Cirrhosis. PLoS ONE, 2015, 10, e0133935.	1.1	36
45	High Dietary Sodium Intake Assessed by Estimated 24-h Urinary Sodium Excretion Is Associated with NAFLD and Hepatic Fibrosis. PLoS ONE, 2015, 10, e0143222.	1.1	38
46	Mesenchymal stem cell therapy for liver fibrosis. Korean Journal of Internal Medicine, 2015, 30, 580-589.	0.7	166
47	Adipose tissue-derived mesenchymal stem cells cultured at high cell density express brain-derived neurotrophic factor and exert neuroprotective effects in a 6-hydroxydopamine rat model of Parkinsonâ€™s disease. Genes and Genomics, 2015, 37, 213-221.	0.5	12
48	Inhibition of hepatic stellate cells by bone marrow-derived mesenchymal stem cells in hepatic fibrosis. Clinical and Molecular Hepatology, 2015, 21, 141.	4.5	44
49	Mesenchymal stem cell therapy for cirrhosis: Present and future perspectives. World Journal of Gastroenterology, 2015, 21, 10253.	1.4	47
50	Assessment for Risk of Bias in Systematic Reviews and Meta-Analyses in the Field of Hepatology. Gut and Liver, 2015, 9, 701.	1.4	13
51	Clinical Characteristics and Outcomes of Acute Hepatitis A in Korea: A Nationwide Multicenter Study. Journal of Korean Medical Science, 2014, 29, 248.	1.1	18
52	Invasive and non-invasive diagnosis of cirrhosis and portal hypertension. World Journal of Gastroenterology, 2014, 20, 4300.	1.4	98
53	Relationship between Tetrahydrobiopterin and Portal Hypertension in Patients with Chronic Liver Disease. Journal of Korean Medical Science, 2014, 29, 392.	1.1	10
54	Effects of candesartan and propranolol combination therapy versus propranolol monotherapy in reducing portal hypertension. Clinical and Molecular Hepatology, 2014, 20, 376.	4.5	19

#	Article	IF	Citations
55	Effect of bone marrow-derived mesenchymal stem cells on hepatic fibrosis in a thioacetamide-induced cirrhotic rat model. BMC Gastroenterology, 2014, 14, 198.	0.8	63
56	Histological improvement following administration of autologous bone marrowâ€derived mesenchymal stem cells for alcoholic cirrhosis: a pilot study. Liver International, 2014, 34, 33-41.	1.9	159
57	The role of growth factors in maintenance of stemness in bone marrow-derived mesenchymal stem cells. Biochemical and Biophysical Research Communications, 2014, 445, 16-22.	1.0	102
58	Adipose tissue-derived mesenchymal stem cells cultured at high density express IFN-Î² and suppress the growth of MCF-7 human breast cancer cells. Cancer Letters, 2014, 352, 220-227.	3.2	84
59	A randomized, open-label study comparing low-dose clevudine plus adefovir combination therapy with clevudine monotherapy in naÃ¯ve chronic hepatitis B patients. Hepatology International, 2014, 8, 375-381.	1.9	7
60	Overview and recent trends of systematic reviews and meta-analyses in hepatology. Clinical and Molecular Hepatology, 2014, 20, 137.	4.5	13
61	The virological response in Koreans infected with HCV genotype 1 did not differ between groups treated with a full dose or reduced dose (â‰¥80Â% full dose) of peginterferon alfa-2a: a prospective randomized multicenter trial. Hepatology International, 2013, 7, 1000-1009.	1.9	2
62	Ultrasonographic scoring system score versus liver stiffness measurement in prediction of cirrhosis. Clinical and Molecular Hepatology, 2013, 19, 389.	4.5	39
63	The usefulness of non-invasive liver stiffness measurements in predicting clinically significant portal hypertension in cirrhotic patients: Korean data. Clinical and Molecular Hepatology, 2013, 19, 370.	4.5	48
64	Beneficial effects of candesartan, an angiotensinâ€blocking agent, on compensated alcoholic liver fibrosis â€•A randomized openâ€label controlled study. Liver International, 2012, 32, 977-987.	1.9	58
65	Revision and update on clinical practice guideline for liver cirrhosis. The Korean Journal of Hepatology, 2012, 18, 1.	1.5	120
66	Cardiovascular Complications of Cirrhosis. , 2012, , 369-393.		0
67	Hepatic vein arrival time as assessed by contrast-enhanced ultrasonography is useful for the assessment of portal hypertension in compensated cirrhosis. Hepatology, 2012, 56, 1053-1062.	3.6	77
68	Relationship between the hepatic venous pressure gradient and first variceal hemorrhage in patients with cirrhosis: a multicenter retrospective study in Korea. Clinical and Molecular Hepatology, 2012, 18, 391.	4.5	12
69	Histological subclassification of cirrhosis using the Laennec fibrosis scoring system correlates with clinical stage and grade of portal hypertension. Journal of Hepatology, 2011, 55, 1004-1009.	1.8	152
70	Portal Hypertensive Gastropathy: Correlation with Portal Hypertension and Prognosis in Cirrhosis. Digestive Diseases and Sciences, 2010, 55, 3561-3567.	1.1	53
71	Haemodynamic evaluation by Doppler ultrasonography in patients with portal hypertension: a review. Liver International, 2010, 30, 1403-1413.	1.9	74
72	Hemodynamic alterations in cirrhosis and portal hypertension. The Korean Journal of Hepatology, 2010, 16, 347.	1.5	79

#	Article	IF	Citations
73	Clevudine Demonstrates Potent Antiviral Activity in NaÃ¯ve Chronic Hepatitis B Patients. Intervirology, 2010, 53, 83-86.	1.2	9
74	Dobutamine stress echocardiography for evaluating cirrhotic cardiomyopathy in liver cirrhosis. The Korean Journal of Hepatology, 2010, 16, 376.	1.5	35
75	Hepatic venous pressure gradient can predict the development of hepatocellular carcinoma and hyponatremia in decompensated alcoholic cirrhosis. European Journal of Gastroenterology and Hepatology, 2009, 21, 1241-1246.	0.8	47
76	Angiotensin receptor blockers are superior to angiotensin-converting enzyme inhibitors in the suppression of hepatic fibrosis in a bile duct-ligated rat model. Journal of Gastroenterology, 2008, 43, 889-896.	2.3	49
77	Cirrhotic cardiomyopathy. Orphanet Journal of Rare Diseases, 2007, 2, 15.	1.2	94
78	Damping index of Doppler hepatic vein waveform to assess the severity of portal hypertension and response to propranolol in liver cirrhosis: a prospective nonrandomized study. Liver International, 2007, 27, 1103-1110.	1.9	65
79	Effect of Propranolol on Portal Pressure and Systemic Hemodynamics in Patients with Liver Cirrhosis and Portal Hypertension: A Prospective Study. Gut and Liver, 2007, 1, 159-164.	1.4	16
80	Recent Variceal Bleeding: Doppler US Hepatic Vein Waveform in Assessment of Severity of Portal Hypertension and Vasoactive Drug Response. Radiology, 2006, 240, 574-580.	3.6	83
81	Role of endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. British Journal of Pharmacology, 2005, 146, 315-323.	2.7	114
82	Acute Hemodynamic Effects of Octreotide and Terlipressin in Patients with Cirrhosis: A Randomized Comparison. American Journal of Gastroenterology, 2005, 100, 631-635.	0.2	104
83	Captopril reduces portal pressure effectively in portal hypertensive patients with low portal venous velocity. Journal of Gastroenterology, 2003, 38, 1150-1154.	2.3	49
84	Comparison of Doppler ultrasonography and the hepatic venous pressure gradient in assessing portal hypertension in liver cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2003, 18, 424-429.	1.4	53